The new Deputy Editor is equally distinguished: Dr. Scott Zamvil at the University of California, San Francisco, has a unique ability to deploy bench immunology for the deeper understanding of human disease, particularly in regard to multiple sclerosis (MS) and neuromyelitis optica (NMO).
In addition to their basic and clinical chops, Drs. Dalmau and Zamvil stand at the center of some of the most exciting areas of biomedicine: antibodymediated neurologic disease and the human immunology around MS and NMO and their treatments.
My departure from N2 represents the incarnation of a bittersweet moment. For the past 10 years I have worked with the Neurology family, first at the flagship green journal and then with the astonishingly committed, energetic N2 team. Recently, when I was offered an opportunity to move with my lab group to Biogen Idec, one of the more challenging considerations was that it would no longer be appropriate to continue with N2. That was the bitter part. The sweetness comes from Dr. Dalmau's willingness to step into the Editor's "office" and Dr. Zamvil's agreeing to join him. In their capable hands, the journal will move forward to attain its full potential because of both the vibrant science in this field and their leadership of this effort. I look forward eagerly to watching future developments. Those of you who have started this journey with me have my enduring gratitude.
EDITOR-IN-CHIEF'S NOTE Richard Ransohoff's departure is bittersweet for all of us on the Neurology team. Richard brought keen editorial, scientific, and clinical intelligence and insight, unparalleled knowledge of his fields, and an abiding loyalty to the green journalsfirst at Neurology, then at N2-to enrich their scope and breadth. N2 launched under his watch, and we could not have wished for a better leader in this effort. He has always offered me sound counsel, for which I am more grateful than I can adequately express. While we hope to keep him as a valued reviewer on N2's Editorial Board, other commitments permitting, we will miss his leadership. At the same time, we wish him only the best as he embarks on a new venture. Richard, we offer the entire team's thanks and congratulations on your new position.
To avoid potential conflict of interest related to Dr. Ransohoff's new affiliation with industry, Drs. Zamvil and Dalmau assisted with editorial duties in the creation of this issue.
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